Announcements Trials
Browse Landscape

Phase

Phase 1 7Phase 2 2Phase 3 1Phase 2/3 1Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 27Neoplasms 22Breast Neoplasms 20Neoplasm Metastasis 18Colorectal Neoplasms 16Stomach Neoplasms 15Recurrence 15Prostatic Neoplasms 15Carcinoma, Hepatocellular 12Pancreatic Neoplasms 11Ovarian Neoplasms 11Head and Neck Neoplasms 11Squamous Cell Carcinoma of Head and Neck 10Lung Neoplasms 10Leukemia, Myeloid, Acute 10Myasthenia Gravis 9Melanoma 9Urinary Bladder Neoplasms 8Lymphoma, Large B-Cell, Diffuse 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Multiple Myeloma 6Lymphoma, Non-Hodgkin 6Liver Neoplasms 6Cholangiocarcinoma 6Carcinoma, Transitional Cell 6Triple Negative Breast Neoplasms 5Small Cell Lung Carcinoma 5Lymphoma, Follicular 5Leukemia, Myelogenous, Chronic, BCR-ABL Positive 5Leukemia 5

Interventions

omburtamab I-131 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × INDUSTRY × Meningeal Carcinomatosis × Clear all
NCT03275402 2024-02-13

131I-omburtamab Radioimmunotherapy for Neuroblastoma Central Nervous System/Leptomeningeal Metastases

Y-mAbs Therapeutics

Phase 2/3 Terminated
52 enrolled 11 charts
CNS

Neuroblastoma, Meningeal Carcinomatosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡